U.S. markets open in 3 hours 2 minutes

Adicet Bio, Inc. (ACET)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
13.49+0.39 (+2.98%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close13.10
Open13.14
Bid12.10 x 800
Ask20.00 x 1800
Day's Range12.78 - 13.50
52 Week Range6.02 - 21.70
Volume52,629
Avg. Volume55,733
Market Cap264.798M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.90
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Adicet Bio to Participate in Upcoming Investor Conferences
    GlobeNewswire

    Adicet Bio to Participate in Upcoming Investor Conferences

    MENLO PARK, Calif. and BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two virtual investor conferences in January. Details of the events are as follows:H.C. Wainwright Bioconnect 2021 Conference The presentation will be available for on-demand viewing starting January 11, 2021 at 6:00 AM ET.B. Riley Securities' Oncology Investor Conference Fireside chat on January 20, 2021 at 3:30 PM ET.A replay of the pre-recorded H.C. Wainwright presentation can be accessed on January 11, 2021 in the investors section of the Company’s website, and a live webcast of the B. Riley presentation can be accessed in the same section of the Company’s website. About Adicet Bio, Inc.Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.Adicet Bio., Inc. Investor and Media Contacts Anne Bowdidge abowdidge@adicetbio.comJanhavi Mohite Stern Investor Relations, Inc. 212-362-1200 janhavi.mohite@sternir.com

  • We're Hopeful That Adicet Bio (NASDAQ:ACET) Will Use Its Cash Wisely
    Simply Wall St.

    We're Hopeful That Adicet Bio (NASDAQ:ACET) Will Use Its Cash Wisely

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

  • Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit
    GlobeNewswire

    Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit

    MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer, will participate in a fireside chat at The JMP Securities Hematology Summit on Tuesday, December 15, 2020 at 2:00 PM ET. A live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.About Adicet Bio, Inc. Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.Adicet Bio., Inc. Investor and Media Contacts Anne Bowdidge abowdidge@adicetbio.comJanhavi Mohite Stern Investor Relations, Inc. 212-362-1200 janhavi.mohite@sternir.com